- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
EASL International Liver Congress The post Transcriptomic analysis revealed distinct mechanisms underlying the synergistic effect of a fatty acid synthase (FASN) inhibitor and resmetirom combination in LDL receptor knockout MASH mice appeared first on Sagimet Biosciences.
EASL International Liver Congress The post Denifanstat and resmetirom combination therapy rapidly decreased atherogenic lipids in healthy adults in Phase 1 open-label trial appeared first on Sagimet Biosciences.
Society for Investigative Dermatology The post Fatty acid synthase (FASN) inhibitors decreased sebum lipids in human sebocytes via inhibition of de novo lipogenesis, supporting FASN as a target for acne treatment appeared first on Sagimet Biosciences.
Keystone Symposia The post Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial appeared first on Sagimet Biosciences.
Keystone Symposia The post Reduction of plasma glycine- and taurine-conjugated bile acids correlated with histological improvements in denifanstat-treated MASH patients in Phase 2b FASCINATE-2 trial appeared first on Sagimet Biosciences.
MASH TAG The post Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial appeared first on Sagimet Biosciences.
AASLD The Liver Meeting The post Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial appeared first on Sagimet Biosciences.
AASLD The Liver Meeting The post Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial appeared first on Sagimet Biosciences.
2025 Fall Clinical Dermatology Conference The post FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial appeared first on Sagimet Biosciences.
9th Annual MASH Drug Development Summit The post Highlighting Mechanism of Action of FASN Inhibitor Denifanstat in MASH appeared first on Sagimet Biosciences.